Art

J-GLOBAL ID：201502218357860909   Reference number：15A0922516

Overexpression of Ephrin A2 receptors in cancer stromal cells is a prognostic factor for the relapse of gastric cancer

癌間質細胞でのエフリンA2受容体の過剰発現は,胃癌再発に対する予後因子である

Author (12)： KIKUCHI Shojiro (Hyogo Coll. of Medicine, Hyogo, JPN) ,  KAIBE Nobuaki (Hyogo Coll. of Medicine, Hyogo, JPN) ,  MORIMOTO Koji (Osaka Univ., Osaka, JPN) ,  FUKUI Hirokazu (36Hyogo Coll. of Medicine, Nishinomiya, JPN) ,  NIWA Hirotaka (36Hyogo Coll. of Medicine, Nishinomiya, JPN) ,  MAEYAMA Yoshihiro (Hyogo Coll. of Medicine, Hyogo, JPN) ,  TAKEMURA Masashi (Hyogo Coll. of Medicine, Hyogo, JPN) ,  MATSUMOTO Masaki (Kyushu Univ., Fukuoka, JPN) ,  NAKAMORI Shoji (Osaka National Hospital, Osaka, JPN) ,  MIWA Hiroto (Hyogo Coll. of Medicine, Hyogo, JPN) ,  HIROTA Seiichi (36Hyogo Coll. of Medicine, Nishinomiya, JPN) ,  SASAKO Mitsuru (Hyogo Coll. of Medicine, Hyogo, JPN)
Material： Gastric Cancer (Web)
Volume： 18  Issue： 3  Page： 485-494 (WEB ONLY)  Publication year： Jul. 2015 
JST Material Number： U0618A  ISSN： 1436-3291  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Thesaurus term： stroma cell ,...
Semi thesaurus term： Ephrin-A2 ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=15A0922516&from=J-GLOBAL&jstjournalNo=U0618A") }}

JST classification (5)： Diagnosis of tumors(=neoplasms)  (GE03020J) ,  Tumors(=neoplasms)of digestive system  (GH04000D) ,  Receptors on cell membrane  (EF04030C) ,  Postoperative treatment and prognosis  (GC07050M) ,  Research methods in genetics  (EC01020N)

Reference (36)：

• Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36-46.
• Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215-21.
• Dodelet VC, Pasquale EB. Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene. 2000;19(49):5614-9.
• Ireton RC, Chen J. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Targets. 2005;5(3):149-57.
• Nakamoto M, Bergemann AD. Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc Res Tech. 2002;59(1):58-67.

Terms in the title (8)： 癌 ,  間質細胞 ,  エフリンA2 ,  受容体 ,  過剰発現 ,  胃癌 ,  再発 ,  予後因子